Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

297.87 -4.79 (-1.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 774,662
Open 303.48
Bid (Size) 297.77 (1)
Ask (Size) 298.92 (1)
Prev. Close 302.66
Today's Range 297.75 - 303.99
52wk Range 233.01 - 325.19
Shares Outstanding 259,428,394
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
10 Analysts Have This to Say About Vertex Pharmaceuticals
 
Via Benzinga

Performance

YTD
+4.14%
+4.14%
1 Month
+1.84%
+1.84%
3 Month
+2.52%
+2.52%
6 Month
+6.23%
+6.23%
1 Year
+18.26%
+18.26%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
Via The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
Via The Motley Fool
2 Explosive Stocks That Could Go Parabolic
Via The Motley Fool
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
Via Benzinga
3 Surefire Stocks That Can Thrive During a Recession
Via The Motley Fool
12-Stock Portfolio -- 25 Growth Stocks to Buy Now
Via The Motley Fool
Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat
Via The Motley Fool
3 Pharma Stocks That Could Benefit from Global Healthcare Trends
Via InvestorPlace
Exelixis Stock Generating Improved Relative Strength Rating
Via Investor's Business Daily
Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
2 Top Biotech Stocks to Buy for the Long Haul
Via The Motley Fool
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
Prediction: These 3 Stocks Will Be in the Dow by 2030
Via The Motley Fool
3 Supercharged Stocks With More Potential Than Any Cryptocurrency
Via The Motley Fool
This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy
Via The Motley Fool
2 Top Stocks to Buy in March and Hold Forever
Via The Motley Fool
Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold
Via The Motley Fool
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
4 Growth Stocks to Buy and Hold Forever
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy Right Now
Via The Motley Fool
7 Cathie Wood Stocks for Your March Buy List
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.